Fresenius SE & Co. (FSNUY)
(Delayed Data from OTC)
$8.46 USD
+0.02 (0.27%)
Updated Aug 7, 2024 03:54 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Fresenius SE & Co. (FSNUY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.00 | $11.00 | $11.00 | 30.33% |
Price Target
Only one analyst offered a short-term price target of $11.00 for Fresenius SE & Co. This represents an increase of 30.33% from the last closing price of $8.44.
Analyst Price Targets (1 )
Broker Rating
Fresenius SE & Co. currently has an average brokerage recommendation (ABR) of 1.86 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.86 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy, representing 57.14% of all recommendations. A month ago, Strong Buy represented 57.14%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/FSNUY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.86 | 1.86 | 1.86 | 1.86 | 1.86 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/14/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/29/2024 | Goldman Sachs | Richard Felton | Hold | Hold |
11/9/2023 | UBS | Graham Doyle | Strong Buy | Strong Buy |
9/5/2023 | Not Identified | Not Identified | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.86 |
ABR (Last week) | 1.86 |
# of Recs in ABR | 7 |
Average Target Price | $11.00 |
LT Growth Rate | NA |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 87 of 253 |
Current Quarter EPS Est: | NA |